Chronix Biomedical's serum DNA assays monitor disease activity and treatment response in MS
Tuesday, April 6, 2010 - 02:42
in Health & Medicine
San Jose, California, April 6, 2010 -- Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS).